Jess Wiggs 8/14/20 Jess Wiggs 8/14/20

One Year Since U.S. Approval, Accelerating Access to New TB Therapy

Read More

Jess Wiggs 8/3/20 Jess Wiggs 8/3/20

TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis

Read More

Jess Wiggs 7/22/20 Jess Wiggs 7/22/20

Mylan Secures DCGI Approval in India for Pretomanid, a Treatment for Highly Drug-Resistant Forms of Tuberculosis

Read More

Jess Wiggs 5/27/20 Jess Wiggs 5/27/20

TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for Pretomanid as part of New Regimen

Read More

Jess Wiggs 3/24/20 Jess Wiggs 3/24/20

COVID-19: a message of solidarity on World TB Day 2020

Read More

Jess Wiggs 3/5/20 Jess Wiggs 3/5/20

Nix-TB Trial Results Published in New England Journal of Medicine

Read More

Jess Wiggs 1/27/20 Jess Wiggs 1/27/20

New Research Assesses Efficacy of Different Doses of Linezolid, Key Medicine Used in Regimens that Treat Drug-Resistant Tuberculosis

Read More

Jess Wiggs 1/16/20 Jess Wiggs 1/16/20

TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China

Read More

Jess Wiggs 10/28/19 Jess Wiggs 10/28/19

TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid

Read More

Jess Wiggs 10/28/19 Jess Wiggs 10/28/19

TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB

Read More

Jess Wiggs 4/18/19 Jess Wiggs 4/18/19

TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis

Read More